As a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 Treatments, Semaglutide or Tirzepatide mimics the action of the body's natural GLP-1 hormone
Weight regain is common when stopping semaglutide, with clinical studies showing patients often regain a significant portion of lost weight within one year of discontinuation
Currently, Tirzepatide and Semaglutide are the leading options for weight loss injections
One such drug, sold under the brand name Wegovy, is approved as a treatment for overweight and obesity
Although GLP-1RAs exert beneficial effects by delaying gastric emptying, enhancing satiety, and reducing caloric intakemechanisms that predominantly promote FM reductionthey are also associated with a loss of lean mass, particularly in the context of substantial weight loss where muscle preservation is critical for metabolic health [77]
The most frequent side effects of semaglutide are mild and tend to disappear over time